On Jul. 28, 2020, Soligenix announced publication of pre-clinical immunogenicity studies for its CiVax program (heat stable COVID-19 vaccine), demonstrating immunity of both broad-spectrum antibody and cell-mediated, rapid onset immunity is possible using the CoVaccine HTﾙ (CoVaccine) adjuvant.

The article, authored by collaborators at the University of Hawaiii at Manoa (UHM), is titled, “CoVaccine HT adjuvant potentiates robust immune responses to recombinant SARS-CoV-2 spike-S1 immunization,” and has been submitted for peer-review to the journal npj Vaccines.